The Exo Alpha Sialidase pipeline drugs market research report outlays comprehensive information on the Exo Alpha Sialidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Exo Alpha Sialidase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Infectious Disease, and Oncology which include the indications Influenza A Virus, H1N1 Subtype Infections, Influenzavirus B Infections, Breast Cancer, and Colorectal Cancer. It also reviews key players involved in Exo Alpha Sialidase targeted therapeutics development with respective active and dormant or discontinued products.
The Exo Alpha Sialidase pipeline targets constitutes close to 23 molecules. Out of which, approximately 20 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 3, 1, 10, and 3 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.
Exo Alpha Sialidase overview
Exo alpha sialidase catalyzes the hydrolytic cleavage of the terminal sialic acid (N-acetylneuraminic acid, Neu5Ac) of a glycan moiety in the catabolism of glycolipids, glycoproteins, and oligosacharides. It recognizes sialyl linkage positions of the glycan moiety as well as the supramolecular organization of the sialoglycoconjugate. In the brain, desorption of the sialic acid by sialidase is essential for synaptic plasticity, learning and memory, and synaptic transmission.
For a complete picture of Exo Alpha Sialidase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
